Key Takeaways
- Base business delivers breakout quarter: Revenue grew 12% QoQ and EBITDA jumped 65% QoQ, both 8-quarter highs, driven entirely by the base business while ibuprofen remained a drag.
- Ibuprofen strategic exit formally underway: Bankers appointed to evaluate options including a sale; the process is expected to conclude in H1 FY27, freeing management attention and capital for the high-margin base business.
- R&D engine restarted after a four-year drought: The company filed its first DMF in April after spending ~₹200 crores on R&D with zero filings in the prior four years; a cadence of 4–5 filings per year is now targeted, though commercialization revenue won't arrive until FY29–FY30.
- Debt reduction on track, debt-free by FY29 targeted: Line of sight to ~₹503 crores of debt by end-May '26 after the rights issue second call; management's internal target is zero debt including working capital debt by FY29.
- What to watch next quarter: Whether tactical ibuprofen price improvement flows into Q1 numbers, the first concrete signal from bankers on the ibuprofen strategic process, and whether the base business can sustain its Q4 momentum without one-off support.
Base Business: The Engine That Worked
- Broad-based, not one-off: Revenue growth came from a healthy order book and utilization across facilities, not spot orders or customer pre-buying; management explicitly ruled out one-off factors.
- Product diversification insulates growth: No single molecule dominates; ~70 products are commercialized, with the top 15–20 driving ~75% of business, so the base business is not hostage to any one product cycle.
- Polymers are a quiet franchise: Solara holds ~50%+ global market share in complex polymer chemicals, a position that provides pricing stability and customer stickiness.
- Spare capacity funds growth without big capex: ~30% capacity is available across existing facilities (excluding the dedicated ibuprofen plant); debottlenecking projects on high-margin lines are adding incremental capacity without greenfield investment.
- Derivatives business stays as-is: The profitable ibuprofen-derivatives business will continue; post any ibuprofen hive-off, Solara would either have the buyer manufacture derivatives or source ibuprofen from a third party.
Sandeep Rao: "No, no, no, Sajal. There's nothing one-off there. And like always, our story continues despite all the headwinds we are facing and the money that we are losing on the ibuprofen business, I think our base business is what's driving the momentum is what's keeping the tailwinds also."
Ibuprofen: The Drag Being Addressed
- Persistent negative EBITDA: The ibuprofen business has generated negative EBITDA for several quarters and "eats out of our existing EBITDA," per management.
- Strategic review formally launched: Bankers have been appointed to evaluate two paths: finding a qualified buyer, or converting the facility into a multiproduct plant focused on non-ibuprofen products. The process started last quarter and is being "seriously pursued."
- Tactical pricing uptick missed Q4: Global ibuprofen realizations improved during Q4 due to Middle East crisis-driven tactical pricing, but the Q4 order book was already locked at agreed prices, so the benefit did not flow through. Some impact may appear in Q1, but it is too early to quantify.
- No backward integration, no technology pivot: Solara does not manufacture the starting material IBB and sources it from third parties; management declined to invest in technology changes or backward integration, framing ibuprofen as a commodity business with negative returns versus the high-margin base business that deserves available capital.
- Vizag decision tied to ibuprofen outcome: The Vizag facility, commissioned in 2024 and mothballed since, will get a clear road map by H1 FY27, contingent on the ibuprofen strategic decision.
- CRAMS polymers carve-out paused: The planned carve-out of polymers in the CRAMS business is on hold until the ibuprofen strategic options are finalized in H1 FY27.
Sandeep Rao: "I see a commodity business, which requires investment and gives me negative returns. And on the other hand, I see a base business that gives me 54%, 55% gross margins and 23%, 25% EBITDA. My preference, I would like to invest money available on the base business so I can grow that business to something a lot more meaningful than the current base business."
R&D Revival After a Lost Half-Decade
- The candid admission: Solara spent roughly ₹200 crores on R&D over 4–5 years and achieved not a single new product filing in the last four years, a fact management volunteered without prompting.
- The restart: The R&D engine has been "entirely revived" with a commercially focused pipeline; the first DMF was filed in the first week of April, and the target is 4–5 filings per year starting FY27.
- Revenue payoff is years away: Because commercialization takes 2–3 years post-filing, impactful revenues and margins from these DMFs will only begin to materialize around FY29–FY30. In a 5-year horizon, new R&D products are expected to sustain growth momentum.
- CRAMS remains subscale and directionless: The CRAMS business generates only ₹10–12 crores annually; management has no strong pipeline or projections and acknowledged it needs to "get back to the drawing table" on CRAMS specifically. It is not factored into the 3-year growth plan.
Sarat Kumar: "So R&D is something which we have spent roughly close to INR200 crores in the past 4, 5 years. However, having said that, at the same time, we are also mindful that our R&D engine has not been able to come up with at least one new product filing in the last 4 years as well."
Margins & Operating Leverage
- Base business margin profile: The base business operates at 54% gross margin and 26% EBITDA margin; management expects to sustain a steady-state EBITDA margin of ~25% plus/minus on the base business over the next 2–3 years, a level demonstrated consistently for several quarters.
- Operating costs held flat QoQ: Flat operating costs against 12% revenue growth delivered superior operating leverage, a dynamic management aims to repeat by growing business on the same opex base.
- Ibuprofen is the margin anchor: The consolidated margin story is dragged down by ibuprofen's negative EBITDA; resolving the ibuprofen overhang is the single largest margin unlock available.
- No greenfield capex to stress returns: Management is not planning any greenfield projects or big capex; incremental investment is limited to debottlenecking high-margin lines where capacity is short.
Sarat Kumar: "We have been maintaining that we will be close to in the range of 25% plus, minus here and there. And this is something which we have been demonstrating quite consistently for the past few quarters, and that is something which should hold true for next few quarters as well."
Balance Sheet & Capital Allocation
- Debt reduction line of sight: Debt is expected to reduce to ~₹503 crores by end-May '26, driven by the second and final call money from the rights issue being utilized by month-end.
- Debt-free by FY29: Management's internal target is to make Solara entirely debt-free, including working capital debt, by FY29.
- No further capital raising: After the rights issue, the company has no plans to raise additional capital through equity or debt at this point.
- Capital allocation preference is clear: Available money will be directed to the base business (54–55% gross margins, 23–25% EBITDA) rather than the commodity ibuprofen business that requires investment for negative returns.
- Mysore facility retained: The 30-acre Mysore site (only 5 acres used) will continue as an intermediate manufacturing site for products within Solara's ecosystem, making a key intermediate for a product finished in Mangalore.
Growth Strategy: The Three-Pivot Plan
- Three pivots for the next three years: (1) Expanding the existing business by seeding new customers for existing products; (2) Driving operational efficiency through capacity debottlenecking, yield improvement, and cost improvement; (3) Wisely managing financials, working capital, and free cash generation.
- Base business is the sole growth driver through FY29: Catalogue generics, polymer APIs, and select intermediates from existing facilities (not Vizag, not CRAMS) will drive revenue and margin growth in FY27, FY28, and FY29.
- Goal to accelerate base business growth: Management aims to grow the base business at a better rate than the ~6% growth achieved versus FY25, which it acknowledges requires significant management time and resources.
- Five actions completed in the turnaround year: (1) Steady leadership and healthy order book; (2) Reignited R&D engine; (3) Debottlenecking for high-margin products; (4) Judicious working capital management; (5) Building a performance-oriented organization.
- Management declined all quantitative outlook: No revenue or EBITDA guidance was provided for FY27 or FY28, and no 3–5-year strategic vision was offered beyond the debt-free target and DMF filing cadence.
Sandeep Rao: "I think these are going to be the three pivots around which our growth is going to be centered over the next 3 years."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Ibuprofen strategic review conclusion | Bankers to evaluate sale or facility repurposing; decision to be communicated | H1 FY27 |
| Vizag facility road map | Clear plan for utilization or repurposing | H1 FY27 |
| Debt reduction | Reduce debt to ~₹503 crores via rights issue second call proceeds | End-May '26 |
| Debt-free target | Zero debt including working capital debt | FY29 |
| DMF filing cadence | 4–5 DMF filings per year | Starting FY27, annually |
| Steady-state base business EBITDA margin | ~25% plus/minus | Next 2–3 years |
| No further capital raising | No equity or debt issuance planned | Indefinite, from current point |
| CRAMS polymers carve-out | On hold pending ibuprofen decision | Until H1 FY27 |
Key Metrics
| Metric | Q4 FY26 |
|---|---|
| Revenue | ₹392 cr, +12% QoQ |
| Gross margin | 47%, +170 bps QoQ; absolute value ₹184 cr |
| EBITDA | ₹61 cr, +65% QoQ |
| EBITDA margin | 16% |
| Base business EBITDA margin | 26%, with gross margins of 54% |
| Developed markets share | 75% of overall sales |
| Debt reduction in FY26 | ~₹158 cr, ~21% reduction; ₹113 cr from rights issue first call, ₹45 cr from operational cash flows |
| Projected debt by end-May '26 | ~₹503 cr, driven by second and final call money proceeds |
| Capacity utilization | ~70%, with ~30% spare capacity available |
| Top 15–20 products concentration | ~75% of total business |
| CRAMS annual revenue | ~₹10–12 cr |
| Polymers market share | ~50% plus globally |
| Annual R&D spend | ~₹25 cr |
| Vizag mothballed facility fixed cost | ₹12–15 cr annually |
| Base business FY26 growth vs FY25 | ~6% |